Brown Stacy, Kennard Benjamin, Thigpen Jim
Department of Pharmaceutical Sciences (SB, BK), Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN.
Allucent (BK), Cary, NC.
J Pediatr Pharmacol Ther. 2025 Jun;30(3):362-366. doi: 10.5863/JPPT-24-00075. Epub 2025 Jun 9.
This study evaluated the chemical compatibility of N-acetylcysteine (NAC) and ondansetron to simplify the treatment of acute nausea and vomiting during intravenous (IV) NAC administration. NAC is commonly used to treat acetaminophen overdose, but its 21-hour IV infusion is often interrupted for ondansetron administration, which can pose risks.
High-performance liquid chromatography with ultraviolet detection was used to quantify NAC. To simulate IV administration, a closed-circuit pump with multiple independent lines, was plumbed with Y-sites to circulate NAC at concentrations matching 30- and 100-kg loading doses and 4-mg ondansetron was pushed into the flow paths. Control lines without ondansetron were also maintained. Samples were collected at 10, 20, and 30 minutes postondansetron introduction. NAC concentrations in single-drug and combination lines were compared using an unpaired -test with Welch's correction (p = 0.05).
The mean concentrations for the 100-kg dose were 55.23 and 55.28 mg/mL for control and with ondansetron, respectively. The 30-kg cohort included 36.38 mg/mL for control and 36.49 mg/mL with ondansetron. The results of the unpaired -test for either weight illustrated that no statistical significance was achieved. Furthermore, the -values of 0.2013 for 100 kg and 0.8556 for 30 kg support a less likely chance of significant difference.
Based on this experiment, ondansetron can be introduced into an NAC infusion via IV push without affecting the NAC concentration in the solution. The likelihood of IV compatibility for NAC and ondansetron could permit no infusion interruptions, reducing unnecessary risk of acetaminophen toxicity.
本研究评估了N-乙酰半胱氨酸(NAC)与昂丹司琼的化学相容性,以简化静脉注射NAC期间急性恶心和呕吐的治疗。NAC常用于治疗对乙酰氨基酚过量,但在其21小时的静脉输注过程中,常因注射昂丹司琼而中断,这可能带来风险。
采用带紫外检测的高效液相色谱法定量NAC。为模拟静脉给药,使用带有多个独立管路的闭路泵,通过Y型接口使NAC以匹配30kg和100kg负荷剂量的浓度循环,并将4mg昂丹司琼注入流动路径。同时也设置了不添加昂丹司琼的对照管路。在注入昂丹司琼后10、20和30分钟采集样本。使用经韦尔奇校正的非配对t检验比较单药组和联合用药组的NAC浓度(p = 0.05)。
100kg剂量组中,对照组和添加昂丹司琼组的平均浓度分别为55.23mg/mL和55.28mg/mL。30kg剂量组中,对照组为36.38mg/mL,添加昂丹司琼组为36.49mg/mL。对任一体重组进行的非配对t检验结果表明,未达到统计学显著性。此外,100kg组的t值为0.2013,30kg组的t值为0.8556,这表明出现显著差异的可能性较小。
基于本实验,昂丹司琼可通过静脉推注加入NAC输注液中,而不影响溶液中NAC的浓度。NAC与昂丹司琼静脉配伍的可能性使得无需中断输注,从而降低了对乙酰氨基酚毒性的不必要风险。